Robert Smith - Gossamer Bio Chief Officer
| GOSS Stock | USD 1.36 0.06 4.23% |
Executive
Robert Smith is Chief Officer of Gossamer Bio
| Age | 56 |
| Phone | 858 684 1300 |
| Web | https://www.gossamerbio.com |
Robert Smith Latest Insider Activity
Tracking and analyzing the buying and selling activities of Robert Smith against Gossamer Bio stock is an integral part of due diligence when investing in Gossamer Bio. Robert Smith insider activity provides valuable insight into whether Gossamer Bio is net buyers or sellers over its current business cycle. Note, Gossamer Bio insiders must abide by specific rules, including filing SEC forms every time they buy or sell Gossamer Bio'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Robert Smith over three months ago Disposition of 826 shares by Robert Smith of Pinnacle West subject to Rule 16b-3 | ||
Robert Smith over three months ago Disposition of 4950 shares by Robert Smith of Pinnacle West at 85.8 subject to Rule 16b-3 | ||
Robert Smith over six months ago Disposition of 4950 shares by Robert Smith of Pinnacle West at 85.8 subject to Rule 16b-3 | ||
Robert Smith over six months ago Disposition of 3000 shares by Robert Smith of NMI Holdings at 31.1854 subject to Rule 16b-3 |
Gossamer Bio Management Efficiency
The company has return on total asset (ROA) of (0.1194) % which means that it has lost $0.1194 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2254) %, meaning that it created substantial loss on money invested by shareholders. Gossamer Bio's management efficiency ratios could be used to measure how well Gossamer Bio manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Allison Nance | Lyra Therapeutics | N/A | |
| Pharm MPH | X4 Pharmaceuticals | N/A | |
| Katie Hogan | Alector | N/A | |
| Stuart Henderson | Passage Bio | N/A | |
| Colin Love | Replimune Group | 66 | |
| Ronan JD | Lyra Therapeutics | 52 | |
| John Bishop | Lyra Therapeutics | 62 | |
| Jonathan JD | Stoke Therapeutics | 34 | |
| Melita Jung | Terns Pharmaceuticals | 48 | |
| Juan MD | Biomea Fusion | N/A | |
| Debra Sieminski | Terns Pharmaceuticals | N/A | |
| MPH DO | Kronos Bio | 60 | |
| Scott Harris | Terns Pharmaceuticals | N/A | |
| Robyn MA | Acumen Pharmaceuticals | N/A | |
| Lindsey Allen | Amylyx Pharmaceuticals | N/A | |
| JD Esq | Passage Bio | 61 | |
| Michael CPA | Nuvectis Pharma | 49 | |
| FASCP MD | Inozyme Pharma | 70 | |
| An Song | 4D Molecular Therapeutics | N/A | |
| Norah Conway | Alector | N/A | |
| Diana Chung | Terns Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -1.23 | ||||
| Return On Asset | -0.12 |
Gossamer Bio Leadership Team
Elected by the shareholders, the Gossamer Bio's board of directors comprises two types of representatives: Gossamer Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Gossamer. The board's role is to monitor Gossamer Bio's management team and ensure that shareholders' interests are well served. Gossamer Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Gossamer Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Colin Rowlings, Senior CMC | ||
| Robert Smith, Chief Officer | ||
| Matt Cravets, Senior Biometrics | ||
| Jeff Boerneke, General Secretary | ||
| Christian Waage, Executive Vice President General Counsel | ||
| Richard MD, Chief Officer | ||
| Mario Orlando, Senior Planning | ||
| Caryn Peterson, Executive Affairs | ||
| Faheem Hasnain, Executive Chairman of the Board, Co-Founder | ||
| Laura Carter, Chief Officer | ||
| Jeanine Anthony, Senior Marketing | ||
| Deanna Weber, Vice President of Human Resources | ||
| Christian JD, Executive Administration | ||
| Bryan Giraudo, COO CFO | ||
| Lisa Nolan, MD Ireland |
Gossamer Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Gossamer Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.23 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.49) % | ||||
| Operating Margin | (3.85) % | ||||
| Current Valuation | 231.02 M | ||||
| Shares Outstanding | 227.22 M | ||||
| Shares Owned By Insiders | 3.28 % | ||||
| Shares Owned By Institutions | 76.49 % | ||||
| Number Of Shares Shorted | 5.72 M | ||||
| Price To Earning | (4.61) X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Gossamer Stock Analysis
When running Gossamer Bio's price analysis, check to measure Gossamer Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gossamer Bio is operating at the current time. Most of Gossamer Bio's value examination focuses on studying past and present price action to predict the probability of Gossamer Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gossamer Bio's price. Additionally, you may evaluate how the addition of Gossamer Bio to your portfolios can decrease your overall portfolio volatility.